RWA Wealth Partners LLC Has $6.67 Million Holdings in Pfizer Inc. $PFE

RWA Wealth Partners LLC cut its holdings in Pfizer Inc. (NYSE:PFE) by 3.5% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 263,332 shares of the biopharmaceutical company’s stock after selling 9,466 shares during the quarter. RWA Wealth Partners LLC’s holdings in Pfizer were worth $6,673,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the business. Clarity Asset Management Inc. acquired a new stake in shares of Pfizer during the fourth quarter valued at about $27,000. Gould Capital LLC boosted its stake in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 493 shares in the last quarter. GKV Capital Management Co. Inc. acquired a new stake in shares of Pfizer during the first quarter valued at about $27,000. North Capital Inc. acquired a new stake in shares of Pfizer during the first quarter valued at about $28,000. Finally, Bayforest Capital Ltd acquired a new stake in shares of Pfizer during the first quarter valued at about $28,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Trading Down 0.3%

Shares of PFE stock opened at $25.07 on Tuesday. The company has a market cap of $142.54 billion, a P/E ratio of 13.34, a PEG ratio of 0.89 and a beta of 0.52. The stock has a 50 day simple moving average of $24.62 and a two-hundred day simple moving average of $24.41. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. The firm had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. During the same quarter last year, the firm posted $0.60 earnings per share. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. Research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer’s dividend payout ratio (DPR) is 91.49%.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on PFE. Berenberg Bank lowered their price objective on Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a research report on Thursday, May 29th. UBS Group raised their price objective on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 30th. TD Cowen lowered their price objective on Pfizer from $32.00 to $28.00 and set a “hold” rating for the company in a research report on Tuesday, April 22nd. Redburn Atlantic lowered their price objective on Pfizer from $29.00 to $27.00 and set a “neutral” rating for the company in a research report on Wednesday, April 30th. Finally, Leerink Partners lowered their price objective on Pfizer from $28.00 to $26.00 and set a “market perform” rating for the company in a research report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and an average price target of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.